“…Particularly, the data regarding DT's expression, distribution and function demonstrate its disease-differential expression (Evers et al, 2018), organism-dependent abundance (Durmus et al, 2015), tissue-specific distribution (Nixon et al, 2016), transporting functional family (Shen et al, 2017), and so on; the data of epigenetic modification on DT describe the DNA/histone methylation & acetylation (Liu et al, 2016), non-coding RNA regulation (Yu et al, 2019), and so on; the data of DT's conformation and structural variations involve species-specific evolution (Dias and Sa-Correia, 2014), the structures of the entire transporter (Penmatsa et al, 2013) and functional conserved/substrate-binding domain (Xue et al, 2016), and so on; the data of DT's exogenous regulation discuss the clinical drug-drug interactions (Kosa et al, 2018), regulatory substrate, inhibitor & inducer (Muller et al, 2018), and so on; the data describing DT's genetic polymorphisms provide the cytogenetic locations (Lewis and Girisha, 2020), disease indication induced by hereditary factor (Karimian et al, 2020), genetic variant & frequency (Veldic et al, 2019), and so on. The above knowledge is valuable for understanding the drug ADME process (Nigam, 2015;Ye et al, 2019), which is thus essential for current research on drug metabolism (Li et al, 2020b;Wang et al, 2020a;He et al, 2021) and disposition (Bai et al, 2016;Kawahara et al, 2020). However, such valuable knowledge is largely dispersed in the literature, which hampers its utility and significantly limits its possibility for comprehensive analysis (Li et al, 2018b;Yang et al, 2020b).…”